Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2024 12:04 ET | Source: ADvantage Therapeutics, Inc.

ADvantage Therapeutics Announces Breakthrough Findings in Alzheimer's Disease Treatment: AD04TM shows immediate symptomatic and disease-modifying properties

PHILADELPHIA, July 30, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics today announced groundbreaking results from a study on AD04™, a novel therapeutic candidate for Alzheimer's disease. Scientists...
February 05, 2024 09:41 ET | Source: Advantage Therapeutics Inc.

Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics

BOCA RATON, Fla. and VIENNA, Austria, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of aging,...
October 02, 2023 11:12 ET | Source: Advantage Therapeutics Inc.

Klogenix’ pioneering research on age-related diseases and longevity gene Klotho finds new home at ADvantage Therapeutics, Inc.

BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Klogenix LLC (“Klogenix” or “the Company”) is pleased to announce that its intellectual property portfolio has been acquired by ADvantage Therapeutics, Inc....
October 02, 2023 10:43 ET | Source: Advantage Therapeutics Inc.

ADvantage Therapeutics Welcomes Esteemed Expert in Alzheimer’s Disease and Klotho Protein, Carmela Abraham, Ph.D. as Chief Science Officer

ADvantage Therapeutics appoints Dr. Carmela Abraham as Chief Science Officer
June 20, 2023 09:00 ET | Source: Advantage Therapeutics Inc.

ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia

MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions with a focus on Alzheimer’s...
April 05, 2023 08:35 ET | Source: Advantage Therapeutics Inc.

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

MIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...